Joint Venture Collaboration with Kyowa Kirin International for established medicines portfolio.
The power of partnerships
Working with partners is the best way to achieve our vision of a world free of pain. At Grünenthal, we never stop searching for new partnerships with like-minded organisations and individuals. By joining forces, we are able to maximise our positive impact on patients worldwide.
of group revenues come from partnering and licensing
R&D collaborations are an important part of this approach. We are always seeking new opportunities to work side-by-side with innovators who share our commitment to developing life-changing treatments, irrespective of the modality involved. Over many decades, we have built a strong network of experts from across disciplines and around the globe. Together, we create novel medications with the potential to make a real difference for patients.
Inorganic growth is another key element of our partnering activities. We grow our business and complement our portfolio by acquiring early or late-stage assets in the therapeutic area of pain, as well as established brands in a broad range of therapeutic areas. Our team has many years of experience, and we use this to ensure fast and effective integration – while maintaining an uninterrupted supply for patients. Established brands with stable sales performance provide funding for further R&D projects. Grünenthal has invested over €2 billion in successful M&A transactions over the past years.
In addition to R&D and acquisitions, we engage in highly effective commercial licensing agreements. Our company is a natural in-licensing partner for businesses that want to bring new projects to market successfully because we are a mid-sized pharmaceutical company with exceptional R&D, regulatory expertise and commercial capabilities. We also engage in out-licensing partnerships that give patients access to our products in territories where we do not have our own presence.
Grünenthal is open to a wide range of collaborative activities including R&D, acquisitions of marketed products and development projects, and sales partnerships or licensing agreements. Our experience has taught us that open minds and open communication are essential factors in this success.